Literature DB >> 19325192

Nicorandil treatment in patients with acute myocardial infarction: a meta-analysis.

Katsuomi Iwakura1, Hiroshi Ito, Atsushi Okamura, Yasushi Koyama, Motoo Date, Yoshiharu Higuchi, Koichi Inoue, Ryusuke Kimura, Hiroyuki Nagai, Michio Imai, Yuko Toyoshima, Makito Ozawa, Norihisa Ito, Yukinori Okazaki, Masahiko Shibuya, Hideaki Suenaga, Asuka Kubota, Kenshi Fujii.   

Abstract

BACKGROUND: It is controversial as to whether nicorandil would have cardioprotective effects in patients with acute myocardial infarction (AMI) who are undergoing reperfusion therapy. A meta-analysis was performed to study the impacts of nicorandil on functional outcomes after AMI. METHODS AND
RESULTS: Randomized prospective cohort or retrospective cohort publications were identified up to October 2007 by means of a computer search of MEDLINE and Google Scholar databases. Two reviewers checked the quality of the studies and extracted data regarding patient and disease characteristics, study design, functional parameters such as Thrombolysis In Myocardial Infarction (TIMI) flow grade after reperfusion, left ventricular ejection fraction (LVEF) and left ventricular end-diastolic volume index (LVEDVI). Seventeen studies were included for the meta-analysis in this study. Nicorandil treatment reduced the incidence of TIMI flow grade < or =2 in 1,337 patients of 10 studies (risk ratio 0.63; 95% confidence interval (CI) 0.44 to 0.91). While no beneficial effect was observed on the peak creatine kinase value, nicorandil treatment was associated with greater LVEF (by 3.7%, 95%CI 1.8 to 5.7%), and lower LVEDVI (by 8.8 ml/kg, -14.4 to -3.3 ml/kg) in 905 patients of 11 studies.
CONCLUSIONS: The meta-analysis demonstrated that nicorandil treatment adjunctive to reperfusion therapy has beneficial effects on microvascular function and on functional recovery after AMI.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19325192     DOI: 10.1253/circj.cj-08-1059

Source DB:  PubMed          Journal:  Circ J        ISSN: 1346-9843            Impact factor:   2.993


  11 in total

1.  Relationship between retrograde coronary blood flow and the extent of no-reflow and infarct size in a porcine ischemia-reperfusion model.

Authors:  Stavros Stavrakis; John Terrovitis; Elias Tsolakis; Stavros Drakos; Argirios Dalianis; Michael Bonios; Dimitrios Koudoumas; Konstantinos Malliaras; John Nanas
Journal:  J Cardiovasc Transl Res       Date:  2010-12-09       Impact factor: 4.132

2.  Advances in Coronary No-Reflow Phenomenon-a Contemporary Review.

Authors:  Ahmadreza Karimianpour; Anbukarasi Maran
Journal:  Curr Atheroscler Rep       Date:  2018-07-05       Impact factor: 5.113

Review 3.  Use of nicorandil in cardiovascular disease and its optimization.

Authors:  Shigeo Horinaka
Journal:  Drugs       Date:  2011-06-18       Impact factor: 9.546

4.  Early Administration of Intracoronary Nitroprusside Compared with Thrombus Aspiration in Myocardial Perfusion for Acute Myocardial Infarction: A 3-Year Clinical Follow-Up Study.

Authors:  Wei-Chieh Lee; Shyh-Ming Chen; Chu-Feng Liu; Chien-Jen Chen; Wen-Jung Chung; Shu-Kai Hsueh; Tzu-Hsien Tsai; Hsiu-Yu Fang; Hon-Kan Yip; Chi-Ling Hang
Journal:  Acta Cardiol Sin       Date:  2015-09       Impact factor: 2.672

5.  No-reflow phenomenon during treatment of coronary in-stent restenosis with a Paclitaxel-coated balloon catheter.

Authors:  Han-Hee Chung; Keon-Woong Moon; Mi-Hyang Jung; Hae-Kyung Yang; Kyung-Seon Park; Ki-Dong Yoo
Journal:  Korean Circ J       Date:  2012-06-28       Impact factor: 3.243

Review 6.  Percutaneous coronary intervention in the elderly with ST-segment elevation myocardial infarction.

Authors:  Lei Gao; Xin Hu; Yu-Qi Liu; Qiao Xue; Quan-Zhou Feng
Journal:  Clin Interv Aging       Date:  2014-07-31       Impact factor: 4.458

7.  Meta-analysis of Nicorandil effectiveness on myocardial protection after percutaneous coronary intervention.

Authors:  Xiao-Tao Zhao; Chun-Fei Zhang; Qing-Jie Liu
Journal:  BMC Cardiovasc Disord       Date:  2019-06-14       Impact factor: 2.298

8.  Initiate Danhong Injection before or after percutaneous coronary intervention for microvascular obstruction in ST-elevation myocardial infarction (DIRECTION): study protocol for a randomized controlled trial.

Authors:  Xiaoyu Zhang; Guihua Tian; Zhaofeng Shi; Yang Sun; Jiayuan Hu; Yin Jiang; Rui Zheng; Shiqi Chen; Chengyu Li; Xinyu Yang; Tianmai He; Songjie Han; Chi Zhang; Lijing Zhang; Yan Liu; Hongcai Shang
Journal:  Trials       Date:  2020-01-08       Impact factor: 2.279

Review 9.  Nicorandil: A drug with ongoing benefits and different mechanisms in various diseased conditions.

Authors:  Lamiaa Ahmed Ahmed
Journal:  Indian J Pharmacol       Date:  2019-11-26       Impact factor: 1.200

10.  Effect of nicorandil treatment adjunctive to percutaneous coronary intervention in patients with acute myocardial infarction: a systematic review and meta-analysis.

Authors:  Jin Zhou; Jing Xu; Aijuan Cheng; Peng Li; Bingwei Chen; Shan Sun
Journal:  J Int Med Res       Date:  2020-11       Impact factor: 1.671

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.